– Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) – – FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC – – Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 – – Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 – – Company to host conference call today at 8 a.m. ET / 5 a.m. PT – SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in...

Q4 FY26 revenues of $1.75 billion; FY26 revenues of $7.26 billion Q4 FY26 net income of $85 million, adjusted EBITDA(1) of $181 million or 10.3% of revenue; FY26 net income of $358 million, adjusted EBITDA(1) of $708 million or 9.7% of revenue Q4 FY26 diluted earnings per share of $1.87, adjusted diluted earnings per share(1) of $2.62; FY26 diluted earnings per share of $7.70, adjusted diluted earnings per share(1) of $10.75 Q4 FY26 cash flows provided by operating activities of $258 million, free cash flow(1) of $336 million; FY26 cash flows provided by operating activities of $609 million, free cash flow(1) of $577 million Q4 FY26 net bookings of $0.6 billion; book-to-bill ratio of 0.3; trailing twelve months book-to-bill ratio of 1.1 Announces FY27 guidance for adjusted diluted earnings per share(1) and reiterates revenue, adjusted...

Roblon’s revenue and earnings for the first quarter of 2025/26 fell short of Management’s guidance at the beginning of the financial year The Board of Directors of Roblon A/S has today considered and approved the interim report for the first three months of 2025/26. Highlights Q1 2025/26 Consolidated revenue amounted to DKKm 29.8, against DKKm 51.1 in the year-earlier period. Whereas the FOC product group improved, the revenue decline in the Composite area was more pronounced than expected. EBITDA before special items was a loss of DKKm 6.3 (a profit of DKKm 6.7). EBIT before special items was a loss of DKKm 9.2 (a profit of DKKm 3.0), and profit/loss from continuing operations before tax was a loss of DKKm 10.4 (a profit of DKKm 4.6). While Management did expect a lower level of activity in the first quarter of 2025/26, both revenue...

— Fourth Quarter Revenues of RMB 676.2 million, down 17.4% year over year — Fourth Quarter Net Loss of RMB 88.1 million, compared with RMB 72.5 million in the same period of 2024 — Full Year Revenues of RMB 4,307.9 million, up 31.0% year over year — Full Year Net Loss of RMB 39.4 million, compared with RMB 193.2 million in 2024 BEIJING, March 16, 2026 (GLOBE NEWSWIRE) — Niu Technologies (“NIU” or “the Company”) (NASDAQ: NIU), the world’s leading provider of smart urban mobility solutions, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsRevenues were RMB 676.2 million, a decrease of 17.4% year over year Gross margin was 15.3%, compared with 12.4% in the fourth quarter of 2024 Net loss was RMB 88.1 million,...

Urgently Delivers Q4 2025 Revenue Growth, Margin Expansion, GAAP Operating Loss Reduction and Non-GAAP Operating Income ASHBURN, Va., March 13, 2026 (GLOBE NEWSWIRE) — Urgent.ly Inc. (Nasdaq: ULY) (“Urgently”), a U.S.-based leading provider of digital roadside and mobility assistance technology and services, today reported financial results for the fourth quarter and year ended December 31, 2025. “We’re pleased to report continued progress and positive momentum in our financial performance. In the fourth quarter, revenue grew 4% year-over-year, gross profit increased 23% to $8.7 million, and gross margin expanded to 26%, which was a 4-point improvement over the prior year period,” said Matt Booth, CEO of Urgently. “For the full year, we significantly reduced operating expenses by delivering an improvement of 29% in GAAP operating...

Please find attached the Business report FY 2025. Attachment13-03-26 # Business Report – JCDecaux – FY2025

AVAILABILITY OF THE 2026 UNIVERSAL REGISTRATION DOCUMENT WITH THE ANNUAL FINANCIAL REPORT Regulated Information Paris, 13 March 2026 Societe Generale hereby informs the public that the French version of the 2026 universal registration document was filed with the French financial markets authority (The Autorité des Marchés Financiers – AMF) on 13 March 2026. The 2026 universal registration document includes the 2025 annual financial report which is made up of notably: •         the sustainability report, in accordance with the transposition into French law of Directive (EU) 2022/2464 of 14 December 2022, commonly known as the Corporate Sustainable Reporting Directive (CSRD) and with Commission Delegated Regulation (EU) 2023/2772 of 31 July 2023 setting out the sustainability reporting standards (European Sustainability Reporting Standards,...

SHANGHAI, March 13, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2025 and provided corporate updates. FINANCIAL HIGHLIGHTSTotal revenue of Junshi Biosciences was approximately RMB2,498 million in 2025, representing an increase of approximately 28% compared to 2024, which was mainly due to the increase in revenue from sales of pharmaceutical products, in particular the domestic sales revenue of the company’s core product, toripalimab, was approximately RMB2,068 million, representing an increase of approximately 38% compared to 2024. Total research and development (“R&D”) expenses...

ATHENS, Greece, March 13, 2026 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (NYSE: “DLNG”) (the “Partnership”), an owner of liquefied natural gas (“LNG”) carriers, today announced its results for the three and twelve months ended December 31, 2025. Twelve months Highlights:Net Income and Earnings per common unit (basic and diluted) of $61.6 million and $1.38, respectively; Adjusted Net Income(1) of $57.1 million and Adjusted Earnings per common unit(1) (basic and diluted) of $1.26; Adjusted EBITDA(1) of $109.2 million; and 99.3% fleet utilization(2).Quarter Highlights:Net Income and Earnings per common unit (basic and diluted) of $15.7 million and $0.38, respectively; Adjusted Net Income(1) of $14.1 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.34; Adjusted EBITDA(1) of $26.9 million; 98.8% fleet...

HOUSTON, March 13, 2026 (GLOBE NEWSWIRE) — U.S. Energy Corporation (NASDAQ: USEG, “U.S. Energy” or the “Company”) today reported financial and operating results for the fourth quarter and year ended December 31, 2025, while highlighting the advancement of the Company’s strategic transformation into a fully integrated industrial gas, energy, and carbon management platform.  MANAGEMENT COMMENTS “2025 was a transformational year for U.S. Energy, one defined by purposeful execution and a forward-looking vision,” said Ryan Smith, Chief Executive Officer of U.S. Energy Corp. “We deliberately optimized and monetized our conventional oil and gas portfolio to fund the development of something far more valuable: a fully integrated industrial gas, energy, and carbon management platform that we believe is fundamentally...